Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Consensus Target Price from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given an average recommendation of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $29.00.

A number of analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler dropped their price target on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th.

Immunome Stock Down 1.1 %

Shares of NASDAQ IMNM opened at $15.79 on Thursday. The firm has a market capitalization of $946.91 million, a P/E ratio of -2.09 and a beta of 1.77. The stock’s 50-day simple moving average is $14.34 and its two-hundred day simple moving average is $16.32. Immunome has a twelve month low of $6.65 and a twelve month high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The firm had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.62 million. As a group, research analysts anticipate that Immunome will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, insider Jack Higgins sold 3,524 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares in the company, valued at approximately $222,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now directly owns 16,615 shares in the company, valued at $231,613.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jack Higgins sold 3,524 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the transaction, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The disclosure for this sale can be found here. 8.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Institutional investors have recently modified their holdings of the business. EntryPoint Capital LLC grew its holdings in Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares during the period. Quest Partners LLC bought a new position in shares of Immunome during the second quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Immunome during the second quarter valued at about $97,000. Arizona State Retirement System grew its stake in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after purchasing an additional 4,129 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.